Lymphoma study tracks brain fog during chemo
NCT ID NCT07443514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how chemotherapy affects memory and thinking in people with a type of blood cancer called diffuse large B-cell lymphoma. Researchers will test cognitive function at the start, after the first chemo cycle, and one year later. They also analyze spinal fluid in some patients to find clues about brain changes. The goal is to understand who is at risk for mental decline and how severe it may be.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 3 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2022
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18 to 80 years * Newly diagnosed diffuse large B-cell lymphoma (DLBCL) planned for treatment with systemic chemotherapy (R-CHOP) with or without intrathecal chemotherapy * Ability to provide written informed consent * For healthy volunteer/control group: relatives of participating patients willing to undergo cognitive testing and questionnaires Exclusion Criteria: * Severe cognitive impairment preventing completion of neurocognitive testing * Severe psychiatric disorder or neurological disease interfering with cognitive assessment * Inability to understand study procedures or complete questionnaires * Refusal or inability to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diffuse large B cell lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institute of Oncology Ljubljana
RECRUITINGLjubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug BL-M08D1 joins standard therapy in fight against aggressive lymphoma
- Can AI spot the lymphoma patients who Won't respond?
- Outpatient immunotherapy tested for hard-to-treat lymphomas
- Can an antibody drug boost standard chemotherapy against an aggressive blood cancer?
- A CAR-T therapy given by injection: can it help Hard-to-Treat lymphoma?
- New drug joins standard chemotherapy in fight against B-Cell lymphoma